HomeCompareSGQRF vs ABBV

SGQRF vs ABBV: Dividend Comparison 2026

SGQRF yields 715.05% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGQRF wins by $1083664.97M in total portfolio value
10 years
SGQRF
SGQRF
● Live price
715.05%
Share price
$0.28
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1083665.07M
Annual income
$849,862,657,200.68
Full SGQRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SGQRF vs ABBV

📍 SGQRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGQRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGQRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGQRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGQRF
Annual income on $10K today (after 15% tax)
$60,779.41/yr
After 10yr DRIP, annual income (after tax)
$722,383,258,620.58/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SGQRF beats the other by $722,383,237,564.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGQRF + ABBV for your $10,000?

SGQRF: 50%ABBV: 50%
100% ABBV50/50100% SGQRF
Portfolio after 10yr
$541832.59M
Annual income
$424,931,340,986.22/yr
Blended yield
78.42%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGQRF
No analyst data
Altman Z
-4.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGQRF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGQRFABBV
Forward yield715.05%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1083665.07M$102.3K
Annual income after 10y$849,862,657,200.68$24,771.77
Total dividends collected$1064808.52M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGQRF vs ABBV ($10,000, DRIP)

YearSGQRF PortfolioSGQRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$82,205$71,505.18$11,550$430.00+$70.7KSGQRF
2$637,314$549,354.84$13,472$627.96+$623.8KSGQRF
3$4,662,299$3,980,372.33$15,906$926.08+$4.65MSGQRF
4$32,202,278$27,213,618.56$19,071$1,382.55+$32.18MSGQRF
5$210,122,965$175,666,527.43$23,302$2,095.81+$210.10MSGQRF
6$1,296,084,845$1,071,253,272.22$29,150$3,237.93+$1296.06MSGQRF
7$7,562,256,317$6,175,445,533.08$37,536$5,121.41+$7562.22MSGQRF
8$41,766,216,830$33,674,602,570.94$50,079$8,338.38+$41766.17MSGQRF
9$218,506,930,724$173,817,078,716.07$69,753$14,065.80+$218506.86MSGQRF
10$1,083,665,073,076$849,862,657,200.68$102,337$24,771.77+$1083664.97MSGQRF

SGQRF vs ABBV: Complete Analysis 2026

SGQRFStock

SouthGobi Resources Ltd., together with its subsidiaries, operates as an integrated coal mining, development, and exploration company in Mongolia, Hong Kong, and China. It primarily explores for coking and thermal coal. The company's flagship project is the Ovoot Tolgoi open pit coal mine located in the Umnugobi Aimag of Mongolia. It also holds interest in Zag Suuj and Soumber Projects. In addition, the company engages in the logistics and trading of coal in Mongolia and China. The company was formerly known as SouthGobi Energy Resources Ltd. and changed its name to SouthGobi Resources Ltd. in May 2010. SouthGobi Resources Ltd. was incorporated in 2002 and is based in Mong kok, Hong Kong.

Full SGQRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGQRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGQRF vs SCHDSGQRF vs JEPISGQRF vs OSGQRF vs KOSGQRF vs MAINSGQRF vs JNJSGQRF vs MRKSGQRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.